Indefinite Delivery Contract 75D30123D15814
Award Date
12/31/22
Last Date to Order
2/28/24
Federal Agency
CDC Pittsburgh
Awardee
Seqirus USA Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded Sanofi Pasteur Inc. a multiple-award indefinite delivery contract with a potential value of $67,076,901.90 to procure adult flu vaccines for 2023-2024. No set-aside was used for this award. Under the terms of the contract, the awardee will deliver flu vaccines to the CDC through the period ending February 28, 2024. The solicitation sought to procure adult flu vaccines in support of the CDC's efforts to prevent the spread of influenza. As the...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $143,324,800 contract is for the procurement of adult influenza vaccines for the 2022-2023 flu season, with a period of performance from the award date of December 31, 2021 through February 28, 2023. The contract does not utilize any set-asides and was awarded...
The Centers for Disease Control and Prevention awarded Seqirus USA Inc. a multiple award indefinite delivery contract with a potential value of $129.8 million to supply pediatric influenza vaccines through February 2028. Task orders will be issued against the contract to procure required vaccines annually to support the CDC's national immunization programs. As a leading manufacturer of influenza vaccines, Seqirus will deliver various formulations of pediatric flu vaccines to the CDC for...
This single award IDV from the Department of Health and Human Services Centers for Disease Control and Prevention to Seqirus USA Inc. has a potential value of $129,537,700 to procure adult flu vaccines through February 2022. The originating solicitation sought to award one or more IDVs for the purchase of influenza vaccines for individuals aged 19 years and older, with a minimum order of 100 doses and maximum of 20 million doses to support adult immunization programs under Section 317(j) of...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services, to Seqirus USA Inc. The contract has a ceiling value of $27,015,000 and is for the delivery of adult influenza vaccines for the 2019-2020 flu season. Seqirus USA Inc., through its Seqirus USA, Inc. division, is a global biotechnology company specializing in the development, manufacturing, and delivery of influenza...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development, manufacturing, and delivery. The $253,319,000 multiple-award IDC has a period of performance from December 31, 2024 to February 28, 2026 and is intended to provide adult flu vaccines to support the CDC's annual immunization programs. Seqirus, through its Seqirus USA, Inc. division, is a...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides for pediatric flu vaccines for the 2023-2024 period. The multiple award contract has a potential value of $220.5 million and was awarded to Seqirus USA Inc. on December 31, 2022. The contract aims to procure pediatric flu vaccines through February 28, 2024 to support the Centers for Disease Control and Prevention's efforts in preventing the spread...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc. to provide pediatric and adult influenza vaccines for the 2022-2023 season. The contract has a total ceiling value of $381,759,818.50 and covers the period from January 3, 2019 to February 28, 2019. Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery, will serve as the prime contractor on this multiple award IDC to...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Seqirus USA Inc., a global biotechnology company specializing in influenza vaccine development and delivery. The $143 million IDC is for the supply of adult influenza vaccines, and a separate $208 million IDC is for pediatric influenza vaccines, to support the CDC's nationwide immunization programs from 2022-2023. Seqirus USA Inc. has also been awarded several other high-value...